# A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

> **NCT01909479** · PHASE3 · TERMINATED · sponsor: **OPKO Health, Inc.** · enrollment: 202 (actual)

## Conditions studied

- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** MOD-4023
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01909479
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2016-08
- **Final completion:** 2018-08
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** Main Study was completed. LT-OLE was discontinued as sufficient safety data has been generated.
- **Last updated:** 2022-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01909479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01909479, "A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01909479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*